



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/30 (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2021/064427

(22) International Filing Date:

28 May 2021 (28.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


20177337.1 29 May 2020 (29.05.2020) EP

(71) Applicant: NUMAB THERAPEUTICS AG [CH/CH];
Einsiedlerstrasse 34, 8820 Wädenswil (CH).(72) Inventors: LICHTLEN, Peter; Kirchstrasse 14, Freien-
bach 8807 (CH). URECH, David; Sonnenblickstrasse 8,
Jona 8645 (CH). HESS, Christian; Uetlibergstrasse 304,
Zurich 8045 (CH). GUNDE, Tea; Turbinenstrasse 33,
Zurich 8005 (CH). SIMONIN, Alexandre; 5 rue de l'Au,
Rosenau 68128 (FR). WARMUTH, Stefan; Zopfstrasse
28, Au 8804 (CH). BROCK, Matthias; Feldstrasse 46,Aesch 8904 (CH). CHATTERJEE, Bithi; Mattenhof 33,
Zurich 8051 (CH). JOHANSSON, Maria; Route de Lac 7,
Denges 1026 (CH). SNELL, Daniel; Im Sunnebüel 8, Thal-
wil 8800 (CH).(74) Agent: WALLINGER RICKER SCHLOTTER TOST-
MANN; Patent- und Rechtsanwälte, Partnerschaft mbB,
Zweibrückenstraße 5-7, 80331 Munich (DE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: MULTISPECIFIC ANTIBODY

Figure 11:

A



(57) **Abstract:** The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (K_D) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising said nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*